Food and Drug Administration (FDA) has approved Ozempic (semaglutide) as the first and only GLP-1 receptor agonist (GLP-1 RA) specifically indicated to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD)
Products are professionally packaged, batch identified and supported by documentation where applicable to assist researchers with traceability and laboratory record keeping
have been used
Pillow, Jinhua Chen, Hui Yao, Zijin Xu, and John Wai, et al., Bioconjugate Chem ., 2017 , 28 , 2086.
It contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a hormone to reduce appetite, increase insulin production, and lower blood sugar
GLP-1 Receptor Agonists for Parkinsons Disease: Promise or Mirage